Global EditionASIA 中文双语Français
Home / China / The fight against novel coronavirus

New inhalation vaccine approved for emergency use

By WANG XIAOYU | | Updated: 2023-12-03 19:48
Share - WeChat

Chinese drugmaker Cansino Biotech said on Sunday that its inhaled COVID-19 vaccine, targeting the XBB.1.5 variant has been approved for emergency use in China.

The adenovirus-vectored vaccine has been recommended by the National Health Commission and has obtained emergency authorization from the National Medical Products Administration, the company said in a notice.

Previously on Friday, three domestic companies announced that their latest COVID-19 vaccines — designed to tackle the XBB.1.5 virus or other variants — have obtained emergency use approval.

Among them is a vaccine based on the messenger RNA technology that was developed by SinoCellTech, a company based in Beijing. The dose tackles multiple variants including XBB.1.

Another new vaccine that was created by CSPC Pharma and is a two-valent dose against XBB.1.5 and BQ.1.

Walvax, a firm based in Yunnan province, also said on Friday that its messenger RNA-based vaccine that is jointly developed with researchers from Shanghai can protect against XBB.1.5 and has been approved for emergency use.

Zhong Nanshan, a noted respiratory illness expert, said earlier this year that six domestic vaccines that can protect against XBB variants — the dominant COVID-19 strain in circulation — were in the pipeline.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349